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Skeletal muscle protein synthesis and degradation in patients with 
chronic renal failure. Muscle protein turnover and amino acid (AA) 
exchange across the forearm were studied in nine postabsorptive 
patients with chronic renal failure (CRF) under unrestricted calorie- 
protein diets and eight controls by using the arterio-venous difference 
technique associated with the 3H-phenylalanine kinetics. In patients 
with CRF: (1) the rate of appearance (Ra) of phenylalanine (Phe) from 
the forearm, reflecting proteolysis, was 27% increased in comparison 
with controls (P < 0.01). Also the rate of disposal (Rd) of Phe, reflecting 
protein synthesis, was increased in patients (P < 0.01). As a conse- 
quence of these counterbalanced alterations, net balance of Phe across 
the forearm, that is, net proteolysis, was not changed. (2) The release of 
total AA from the forearm was not different from controls. Valine and 
ketoisocaproate release was reduced (P < 0.05). Serine uptake was not 
detectable. (3) Net proteolysis and the Rd/Ra ratio were inversely and 
directly, respectively, related to arterial [HCO;] (P < 0.02 and P < 0.03, 
respectively). (4) Moreover, net proteoiysis and Phe RdIRa ratio were 
directly and inversely, respectively, correlated with plasma cortisol 
(P  < 0.01 and < 0.005, respectively). Plasma cortisol was in the normal 
range and inversely related to arterial [HCO; 1 (P < 0.02). (5) While in 
controls phenylalanine appearance from the forearm was inversely 
related to insulin levels, no correlation was found in patients. In 
conclusion, in patients with CRF, forearm Phe kinetics indicate the 
existence of an increased muscle protein turnover. Changes in protein 
synthesis and degradation are well balanced and net proteolysis is not 
augmented. However, net proteolysis increases in proportion to the 
degree of metabolic acidosis because protein synthesis rises less than 
protein breakdown. Variations in net proteolysis are best accounted for 
by changes in plasma cortisol levels, suggesting that cortisol plays an 
important role in variations in muscle net proteolysis in patients with 
CRF and metaboIic acidosis. A resistance of muscle proteolysis to basal 
insulin levels likely takes place. 
Uremic patients, mainly dialysis patients, show a high prev- 
alence of protein malnutrition [I] which in some case may be 
severe. There is also evidence [I ,  21 that protein malnutrition 
may be present before the beginning of dialysis therapy, and 
this condition is commonly attributed to an inadequate intake of 
nutrients or superimposed illnesses [I]. However, it is still 
unknown if in humans chronic renal failure (CRF) per se affects 
muscle protein metabolism. 
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Most studies investigating the effects of chronic uremia on 
muscle protein metabolism have been performed in rats. Re- 
sults, somewhat contradictory, suggest the existence of an 
altered protein turnover. In starved uremic rats protein synthe- 
sis has been reported to be reduced [3, 41 and protein break- 
down increased [3]. In fed uremic rats muscle protein synthesis 
can be either decreased [S] or normal [3, 41. An increase in net 
proteolysis, that is, the resultant between protein synthesis and 
degradation, has been reported in uremic animals [3, 5-71. 
Insulin [6] or epinephrine [8] resistance, or an abnormal energy 
metabolism [3] in muscle leading to body loss of fat, have been 
proposed as mechanisms causing an increased proteolysis. 
More recently, metabolic acidosis has been shown to have a 
major role in increasing protein degradation in uremic rats [9]. 
In patients with CRF, evidence for an increased muscle 
proteolysis has been more ditlicult to obtain. A number of 
alterations in muscle amino acid (AA) levels [lo] as well AA 
exchange across peripheral tissues in the postabsorptive [ I l ,  
121 and protein-fed state [13, 141 have been described even in 
patients with moderate CRF. The same studies have shown a 
normal net release of phenylalanine, tyrosine and lysine from 
the leg in postabsorptive patients, indicating that muscle net 
proteolysis is not increased. However, the arterio-venous dif- 
ference technique used in these studies reveals only the net 
balance of AA across the organs and provides no information 
on the components of protein turnover, that is protein synthesis 
and breakdown. It has to be underlined that the amount of 
protein synthesized and degraded every day is very large and 
therefore even little changes in muscle protein turnover may be 
critical for maintaining lean body mass [IS]. 
Recently, a combined technique in which the method of 
arterio-venous differences for phenylalanine across the forearm 
is associated with steady state kinetics of 3H-phenylalanine, has 
allowed the estimation of rates of muscle protein synthesis and 
breakdown [16]. Since phenylalanine is not metabolized in 
muscle [17], the rate of phenylalanine disposal across the 
forearm reflects its rate of incorporation into protein, while the 
rate of appearance of phenylalanine in venous blood reflects its 
release from muscle protein breakdown. Accordingly, this 
procedure has been used in order to evaluate protein turnover 
across the forearm in well-nourished patients with CRF, in the 
postabsorptive state. 
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Methods
Subjects
Two groups of subjects were studied. The control group
consisted of eight healthy volunteers (6 men and 2 women) aged
40 4 years (body wt 73 4 kg). Arterial bicarbonate
concentration was 24 0.3 mmol/liter and hematocrit 40 2%.
The second group consisted of nine patients with CRF (7 men
and 2 women) aged 49 5 years (body wt 68 3 kg). Creatinine
clearance was 24 3 mlImin 1.73 m2. Blood urea was 23 1
mmollliter, arterial bicarbonate 20 0.5 mmollliter and hemat-
ocrit 35 2%. Serum phosphate was 41 2 mg/liter. Serum
sodium, potassium and calcium were in the normal range.
Neither group of subjects had history or evidence of gastro-
intestinal or hepatic disease, congestive heart failure, diabetes
mellitus or other endocrinopathies. Both control subjects and
patients were 105 3% and 101 2%, respectively, within
their desirable body weight based on Metropolitan Life Insur-
ance Tables [18]. For at least three months before admission,
both patients and controls were on a diet that provided 30 to 35
kcal and 0.85 to 1 g of protein/kg body weight as assessed by
dietary histories. All subjects were in good nutritional balance
as evaluated by anthropometric measurements and biochemical
determinations, such as serum albumin, transferrin and pseudo-
cholinesterase activity. The average forearm volume was the
same in patients and controls (967 60 and 967 58 ml,
respectively). Urea excretion was strictly comparable in both
groups and consistent with the protein intake reported above
(388 45 mmollday in patients and 372 50 mmollday in
control subjects).
All patients were informed of the nature, purpose, procedure
and possible risks before their voluntary consent was obtained.
Procedures were in accordance with the Helsinki Declaration.
Procedures
The study was performed in the postabsorptive, overnight
fasted state. Catheters were introduced into a brachial artery
and, in a retrograde fashion, into an ipsilateral deep forearm
vein. Patency of cathethers was maintained by a slow infusion
of saline. Through a contralateral arm vein subjects received a
primed (— 11 MCi), continuous (0.45 sCiImin) 210-minute
infusion of L-(ring-2,6—3H) phenylalanine. After a 150-minute
tracer equilibration period, blood samples were taken simulta-
neously from the brachial artery and the ipsilateral deep fore-
arm vein at 20 minute intervals during a 60 minute period. For
one minute before and during withdrawal of each blood sample,
blood flow to the hand was excluded by a sphygmomanometer
cuff inflated around the wrist to 200 mm Hg. Plasma flow across
the forearm was determined immediately after each arterio-
venous sampling with the dye-dilution method [19]. Indocya-
nine Green Dye (Becton and Dickinson, Cockeysville, Mary-
land, USA) was dissolved in distilled water and, successively,
was diluted with 0.9% saline containing 5% albumin. The dye
was infused (0.3 mg/mm) directly intra-arterially for five min-
utes with the wrist cuff inflated. Samples were collected very
slowly from the deep vein in order to avoid any perturbation of
flow. Recirculation of the dye was found to be negligible (5%) as
measured in a sample taken from the vein of the opposite arm.
Blood flow was calculated by dividing plasma flow by (1-
hematocrit). Forearm volume was measured in a large plastic
cylinder by water displacement from the tip of the arterial
catheter to the upper edge of the wrist cuff [20].
Analytical methods
Amino acids (AA) were determined on whole blood. Perchlo-
nc acid (0.75 mol/liter) was used for blood protein precipitation.
An aliquot of the supernate was neutralized with a buffered
solution, stored at —25°C, and used for the assay of glutamine
and glutamate. Another aliquot was stored at —25°C and used
for the determination of other AA [21, 22]. Blood samples were
processed immediately after withdrawal. AA were measured in
triplicate by the ion exchange chromatographic technique (3A30
Amino Acid Analyzer, Fisons Instr. Milan, Italy) employing
lithium buffers [22]. Glutamine and glutamate were determined
enzymatically [23]. Ketoisocaproate levels were determined in
plasma according to [24]. Phenylalanine specific activity was
determined in plasma [16, 25]. Briefly, 2 ml of acidified plasma
were placed on a Dowex-500 cation-exchange resin column
(Bio-Rad, Richmond, California, USA). After washing with
0.01 N HC1, the amino acids retained on the column were eluted
with 4 M NH4OH. The eluate was vacuum centrifuged to
dryness, and the residue was dissolved with 2% trichloroacetic
acid. Phenylalanine specific activity was measured in this
extract by HPLC [16, 25]. The phenylalanine peak eluted at 15
to 17 minutes. The fraction so obtained was collected into
scintillation vials and subsequently counted for 3H radioactivity
(Beckman LS 1701 scintillation counter, Fullerton, California,
USA). The calculation of phenylalanine specific activity was
performed by dividing the 3H radioactivity by the HPLC-
derived phenylalanine concentration. Previous work from our
laboratory has shown that 3H phenylalanine specific activity is
very similar in plasma and whole blood samples (ratio of whole
blood to plasma specific activity = 0.96±0.04; unpublished
results). The concentration of Indocyanine Green Dye in the
infusate and in plasma samples, after appropriate dilution, was
measured spectrophotometrically at 805 nm [26]. Plasma insulin
and cortisol were determined by radioimmunoassay (Diagnostic
Products L.A., USA and Farmos, Orion Corporation, Turku,
Finland, respectively). Arterial blood pH and pCO2 were esti-
mated at 37°C with a pHM 72/BMS3 apparatus (Radiometer
Co., Copenhagen, Denmark). Blood bicarbonate concentra-
tions were calculated using the Henderson-Hasselbalch equa-
tion. Hematocrit was measured by a microcapillary procedure.
All other serum chemical measurements were determined by
the routine clinical chemistry laboratory.
Calculations
Forearm plasma flow was estimated by dividing the cardio-
green infusion rate (mg/mm) by its level (mg/mI) in the venous
plasma. Values are the mean of four determinations obtained
each from three sets of samples at 20 minute intervals.
The net forearm balance for AA was calculated from the Fick
principle:
Net balance = ([A] — [V]) . blood flow
where [A] and [V] are the arterial and venous concentrations,
respectively.
Phenylalanine is not metabolized in muscle, thus the rates of
disposal of phenylalanine across the forearm at steady state
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reflect its rates of incorporation into protein, while tissue rates
of appearance of phenylalanine reflect its release from tissue
protein breakdown. Net balance expresses the difference be-
tween the rate of disposal of arterial phenylalanine (Rd) and the
rate of appearance into veins of muscle release of phenylalanine
(Ra) [16, 25]:
Net balance = Rd — Ra
In the postabsorptive condition, as evaluated in the present
study, net balance of phenylalanine across the forearm is
negative and expresses net proteolysis.
Phenylalanine Ra was calculated as follows [16, 25]:
Ra = blood flow x [VI x (1 — SAv/SAa)
where [V] is the venous blood level of phenylalanine and SAa
and SAy indicate the specific activity (dpm/nmol) of phenylal-
anine in artery and vein, respectively. The term (1 — SAv/SAa)
expresses the dilution of tracer specific activity across the
forearm from unlabeled phenylalanine released by muscle.
Muscle disposal of unlabeled phenylalanine (Rd) was calcu-
lated as follows:
Rd = Ra + net balance
Whole body phenylalanine flux was calculated from the rate
of tracer infusion (dpm/min) divided by the 3H phenylalanine
specific activity in arterial blood [16].
Controls and patients with CRF were compared by analysis
of variance by using a completely randomized design; a ran-
domized block design was applied to the analysis of variance for
paired data [27]. Analyses of simple regression and correlation
[27] were used to evaluate relationships of phenylalanine net
release (that is, net proteolysis), rate of appearance and the
ratio of rate of disposal to rate of appearance (dependent
variables) with arterial bicarbonate, plasma cortisol and insulin
(independent variables). Stepwise multiple regression analysis
[27] was used in order to discover which proportion of varia-
tions in phenylalanine net release was accounted for by bicar-
bonate and cortisol levels and by the model. Bicarbonate and
cortisol levels were adequately transformed in order to linearize
their relationships with phenylalanine net release. Values are
given as nmol/min 100 ml forearm (mean sEM).
Results
Phenylalanine kinetics across the forearm
Blood flow across the forearm was slightly but not signifi-
cantly higher in patients (6.4 0.5 vs. 5.3 0.3 mllmin 100 ml
Table 1. Rates of appearance and disposal and net release of
phenylalanine across the forearm in 9 patients with chronic renal
failure and in 8 subjects with normal renal function in the
postabsorptive state (nmol/min 100 ml forearm)
Rate of
appearance
Rate of
disposal
Net
release
CRF 61 3 40 3 21 2
Controls 48 3 29 3 19 2
a Significantly different from the corresponding values in controls, P
<0.01
in controls). Both in patients and controls venous blood levels
of phenylalanine were significantly higher (46 2 in patients, 44
2 prnollliter in controls) than the arterial ones (43 2 in
patients, 40 3 prnol/liter in controls; P <0.001), indicating net
release of phenylalanine from muscle. In both groups the
respective arterial and venous levels were not statistically
different. Arterial and deep venous plasma 3H phenylalanine
specific activities are shown in Figure 1A. Plasma specific
activities were stable throughout the study. Specific activities in
venous blood were lower (P < 0.001) than in arterial blood,
indicating isotope dilution across the forearm and phenylalanine
release. However, the dilution of specific activity in venous
blood was higher in patients (Fig. 1B), indicating a greater
phenylalanine release from muscle.
In patients, phenylalanine Ra from the forearm was 27%
increased (Table 1) in comparison with controls, indicating an
increased protein breakdown. Phenylalanine Rd was also in-
creased in patients. As a consequence of these counterbalanced
alterations net release of phenylalanine from the forearm, that is
net proteolysis, was not changed.
In patients whole body phenylalanine flux was 16% increased
(0.64 0.02 tmolIkg/min vs. 0.55 0.02 p.mol/kg/min in
controls; P < 0.05).
Amino acid balance across the forearm
Patients with CRF had higher arterial blood levels of proline,
citrulline, and cyst(e)ine (P < 0.05 to 0.001) and lower levels of
serine, valine, tyrosine and ketoisocaproate (P < 0.05 to 0.01;
Table 2). Plasma levels of insulin (8.6 0.72 in patients and 7.6
0.83 mU/liter in controls) and cortisol (300 37 in patients
and 330 65 nmolJliter in controls) were similar in the two
groups.
In patients, the release of total AA from the forearm was not
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Fig. 1. Plasma 3H phenylalanine specific
activity in the artery and in the forearm deep
vein (A) and the ratio of specific activities in
the vein to the artery (B) in patients with CRF
(j) and controls (•). Abbreviations are:
SAy, vein specific activity; SAa, artery
specific activity.
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Table 2. Arterial concentration and forearm exchange of amino acids (AA) and ketoisocaproate (KIC) in 9 patients with chronic renal failure
and 8 subjects with normal renal function in the postabsorptive state
Arterial concentration
nmol/ml
Forearm exchange
nmollmin 100 ml
Controls CRF Controls CRF
Taurine 202 8 175 17 —22 17 —13 7
Threonine 90 3 96 7 —29 6 —41 9C
Serine 102 7 85 6 +20 7C +6 9
Glutamate 136 14 138 10 +104 14C +142 14c.d
Glutamine 528 31 493 26 —129 22C —118 27C
Proline 155 8 217 12C —18 7C —14 9
Glycine 257 20 270 12 —41 7C —38 9C
Alanine 222 24 209 9 —185 2lC —270 34
Citrulline 28 2 80 4f —6 4 —9 6
Valine 187 7 160 l0 —25 3C —15
Cyste(i)ne
Isoleucine
44 5 84
45 5 52 2 +20 7C—15 4C +15 2C—10 3b
Leucine 94 7 100 7 —30 6C —24 5
Tyrosine 44 4 36 2 —16 3C —20 4C
Phenylalanine 40 3 43 2 —19 2C —21 2C
Ornithine 69 7 73 7 +1 5 +7 4
Lysine
Histidine
148 8 149 6
72 7 83 4 —42 8C—12 3' 39 8C7 2b
Arginine 58 4 67 4 —13 7 —20 5b
KIC 35 3 26 2 —12 5b +2 l
Total AA 605 70 617 92
Total essential AA 174 21 161 27
Total non-essential AA 431 52 456 66
Probability that A-V differences do not differ from zero: a P < 0.05; b P < 0.025; C P < 0.01 or less
Significance of difference from the corresponding value in controls: d P < 0.075; e P < 0.05; P < 0.025 or less
Table 3. Factors influencing muscle net proteolysis in patients with
CRF and in controls
Controls CRF
Variable r P r P
Arterial EHCOfl —0.387 NS —0.775 <0.015
Plasma insulin —0.67 <0.075 0.233 NS
Plasma cortisol —0.301 NS 0.843 <0.005
different from controls (617 92 in patients vs. 605 70
nmol/min 100 ml in controls). The same was true for total
essential AA (EAA) and total non-essential AA (NEAA). Also
the release of tyrosine and lysine, which are not metabolized by
muscle and, analogously to phenylalanine, express net proteol-
ysis, was not different in the two groups.
In patients, abnormalities were observed for a few AA.
Valine and ketoisocaproate were released in reduced amounts
into the forearm vein, whereas the release of alanine and the
uptake of glutamate tended to rise. Finally, serine uptake was
not detectable.
Factors influencing muscle net proteolysis in CRF
Table 3 shows the relationships between muscle net proteol-
ysis and arterial [HCO 1, plasma cortisol and insulin in
patients with CRF and controls.
In CRF patients net proteolysis was inversely related to arte-
rial [HCOfl (Table 3 and Fig. 2A): the lower the arterial
EHCO1, the higher was net proteolysis. Furthermore, the
phenylalanine Rd/Ra ratio was also correlated with arterial
[HCOj ] (Fig. 2B). These data indicate that protein synthesis
augments less than protein breakdown as long as acidosis
becomes more severe. Interestingly, plasma cortisol was in-
versely related to arterial bicarbonate (r =
—0.76; P < 0.02).
Moreover, net proteolysis and phenylalanine RdIRa ratio were
directly and inversely correlated, respectively, with plasma
cortisol levels (Fig. 3). There was no correlation between net
proteolysis and insulin levels.
Multiple regression analysis was used in order to discover
which proportion of variations in net proteolysis (dependent
variable) was accounted for by bicarbonate and cortisol levels
(independent variables), which were significantly related in
simple regression analysis. Cortisol was the only predictor of
variations in net proteolysis observed in patients (Table 4).
Factors influencing forearm valine release in CRF
In controls, valine release from the forearm was inversely
related to plasma insulin, whereas no correlation was found in
renal patients (Table 5). On the other hand, in patients, but not
in controls, valine release was directly related to cortisol levels.
In addition, while in controls valine release was directly related
to phenylalanine Ra, such a correlation was not found in
patients. In CRF valine release was inversely related to phe-
nylalanine Rd, while such a correlation was not found in
controls.
Discussion
The measurement of forearm phenylalanine kinetics, per-
formed in the present study, demonstrates that in patients with
moderately severe CRF and under unrestricted calorie-protein
diets the forearm takes up and releases higher amounts of
phenylalanine than in controls, indicating the presence of a high
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Table 4. Determinants of muscle phenylalanine net release in chronic renal failure using stepwise multiple regression analysis
Variable
Regression
coefficient
Partial
r2 P
Model
r2 P
Plasma cortisol —3499.8 0.845 <0.007 0.845 <0.007
Blood [HCO1 242,2 0.001 NS 0.846 <0.002
Cortisol and [HCOfl were transformed as 1/cortisol and l/[HCOfl.
Table 5. Factors influencing valine release from the forearm in
patients with CRF and in controls
Cont
r
rots
P
CRF
r P
Insulin —0.824 <0.02 0,126 NS
Cortisol 0.154 NS 0.746 <0.039
Phenylalanine Ra 0.700 <0.05 —0.360 NS
Phenylalanine Rd 0.494 NS —0.775 <0.029
protein turnover. Changes in protein turnover, namely protein
synthesis and degradation, are fairly well balanced and net
proteolysis is on the average not augmented. However, net
proteolysis increases in proportion to the degree of metabolic
acidosis. Net balance of total AA across the forearm is un-
changed.
So far, only few studies have been performed on protein
metabolism in patients with CRF and carried out by whole body
isotope dilution techniques [28—31]. It has been found that
well-nourished adults in hemodialysis have a decreased protein
synthesis in the presence of a normal protein breakdown [28].
Furthermore, a normal protein degradation, but an enhanced
proteolytic response to thyroid hormones has been reported in
hemodialysis patients [29]. In patients with moderately severe
CRF, whole body protein synthesis and degradation and AA
oxidation have been reported to be normal [30] or decreased
[31]. Finally, in patients on low protein diet, AA oxidation and
protein degradation decrease as in normal subjects receiving
similar diets [30]. Discrepancies among these results may
depend, at least in part, on different clinical settings, calorie
and/or protein intake and acid-base status. In addition, the
aforementioned studies cannot provide adequate information
on muscle protein turnover, which contributes only for a
fraction to total protein turnover [32].
The current study demonstrates the occurrence of a distur-
bance in muscle protein metabolism taking place in CRF
patients rather precociously. Data relative to phenylalanine
kinetics obtained in controls are fairly comparable with those
reported in normal subjects [16, 25]. In the present study, the
forearm phenylalanine kinetics were calculated using the arte-
rial phenylalanine specific activity as the precursor of the
intracellular pool, according to the most commonly used pro-
cedure [16]. Alternatively, the use of venous phenylalanine
specific activity as the reference pool, rather than the arterial
one, has been proposed [16]. By using this calculation, absolute
values for forearm phenylalanine turnover are higher both in
A r= —0.77; P< 0.02 B r— 0.72; P< 0.0390U)C')
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Fig. 3. Relationships of (A) forearm
phenylalanine net release and (B) the ratio
phenylalanine rate of disposal/phenylalanine
rate of appearance to plasma cortisol in
patients with CRF in the postabsorptive state.
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controls (Ra 60 5 and Rd = 41 4 nmollmin 100 ml) as
previously observed [16], and in CRF patients (Ra = 77 4 and
Rd = 56 5 nmol/min 100 ml), again confirming higher
phenylalanine turnover rates in patients than in controls (P <
0.05). Accordingly, independently of the adopted calculation
procedures, differences between patients and controls remain
unaffected. It has to be remembered that forearm amino acid
exchange reflects mainly muscle metabolism, but also skin and
adipose tissue may influence the exchange of amino acids
across the forearm.
In patients studied here, the altered protein metabolism does
not lead to an increase in muscle net proteolysis, likely in
accordance with the welfare of patients. Actually, when whole
body protein turnover was evaluated in more severe clinical
settings such as sepsis or trauma, a net protein catabolism, a
consequence of an increased whole body degradation and a
lesser whole body protein synthesis, was detected [33]. An
important role in promoting protein degradation can be played
by metabolic acidosis. In vitro metabolic acidosis seems to
accelerate protein degradation [34] without any effect on pro-
tein synthesis. On the other hand, there is evidence that in vivo
metabolic acidosis is associated with increased whole body
protein turnover, including both protein synthesis and degrada-
tion [35, 36]. Evidence that metabolic acidosis enhances muscle
protein catabolism in humans is indirect. Growth is stunted in
children with metabolic acidosis and can be partially corrected
after bicarbonate therapy [37]. In patients with CRF, correction
of metabolic acidosis improves nitrogen balance [38] and re-
duces the 3-methyl-histidine/creatinine ratio in urine [39]. Data
obtained in the present study support the role of metabolic
acidosis in increasing net muscle proteolysis in CRF. Changes
in muscle protein turnover observed in CRF in the present
study could lead, on a long term basis, to a significant loss of
lean body mass, considering that the amount of muscle protein
synthesized and degraded every day is very large. Patients
studied here had a mild metabolic acidosis. It is reasonable to
suppose that a greater net protein degradation can occur in
more acidotic patients.
It is still uncertain if the effects of metabolic acidosis on
muscle protein metabolism are direct or mediated by glucocor-
ticoids [9]. In rats, metabolic acidosis stimulates glucocorticoid
production [34, 40]. In patients reported here, cortisol levels
were within the normal range, but inversely related to arterial
bicarbonate concentration. At the same time, net proteolysis
was directly related to cortisol levels. Moreover, multiple
regression analysis showed that plasma cortisol was the only
predictor of variations in net proteolysis observed in CRF
patients. Cortisol is the counter-regulatory hormone represent-
ing the most powerful stimulus for protein catabolism [33].
Furthermore, skeletal muscle appears to be a primary target for
the physiological response to cortisol [33]. While corticoste-
roids in pharmacological doses reduce protein synthesis [41], in
humans an increase in cortisol levels in the physiological range
augments whole body protein degradation [42]. However, cor-
tisol levels in patients reported by this study were in the normal
range; this finding supports the hypothesis that cortisol primes
the metabolic pathways of protein degradation which are stim-
ulated by metabolic acidosis, somewhat in accordance with
data obtained in uremic rats [34].
Insulin is an important anabolic hormone. Recent studies
performed by the forearm perfusion technique have shown that
in normal postabsorptive subjects, insulin exerts its primary
effect on protein metabolism by inhibition of muscle proteolysis
[16, 43], without any effect on protein synthesis. In the current
study plasma insulin levels were not different in patients and
controls. However, while in controls phenylalanine appearance
from the forearm was inversely related to insulin levels (Fig. 4),
no correlation was detected in patients. Such an observation
suggests that in renal postabsorptive patients a resistance of
muscle proteolysis to basal insulin levels takes place.
Data presented here confirm previous results obtained when
arterio-venous differences for AA and branched-chain keto
acids (BCKA) across the leg [11] and forearm [44] were
evaluated in renal patients and controls. In fact, in the present
study a reduced release of valine and ketoisocaproate from the
forearm has been observed in patients. Metabolic acidosis
increases muscle BCAA degradation by stimulating the activity
of BCKA dehydrogenase in uremic rats [45]. Furthermore, in
chronic hemodialysis patients intracellular muscle levels of
valine are reduced and directly correlated with arterial [HCOfl
[46], supporting the responsibility of acidosis for increased
valine degradation in humans. In the current study, no corre-
lation between valine release and arterial [HCOfl has been
observed. However, this finding may be meaningless if one
considers that metabolic acidosis could affect valine release by
muscle by increasing both valine appearance from proteolysis
and valine degradation. The diminished forearm release of
valine could be accounted for by the reduced intracellular levels
of the same AA [46]. As an additional observation in the present
study valine release was inversely related to phenylalanine
A r= —0.81; P< 0.02
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Fig. 4. Relationships between phenylalanine
rate of appearance from the forearm and
plasma insulin levels in controls (A) and in
patients with CRF (B) in the postabsorptive
state.
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disposal in patients, but not in controls. Thus, in CRF, an
increased uptake of this AA could contribute to the reduced net
release of valine. Because no correlation between valine release
and insulin levels has been detected in renal patients, at
variance with controls, it is possible that a defective muscle
metabolism and/or transport of valine occurs at basal insulin
levels.
In the current study, contrary to valine, leucine forearm
release as well as its blood levels were in the normal range.
Actually, blood leucine levels decline in more advanced CRF,
as reported elsewhere [121. The reduced release of ketoisocap-
roate in the presence of an unmodified leucine release can
explain the increased leucine/ketoisocaproate ratio, already
reported in patients with CRF [44, 47].
In normal postabsorptive subjects, alanine is the AA released
from peripheral tissues at the highest rates. An increased
muscle release of alanine has been found in uremic rats [5, 8].
The present study demonstrates that in patients, alanine re-
lease, somewhat increased, is directly correlated with both
phenylalanine Ra (r = 0.648; P < 0.05) and net proteolysis (r =
0.683; P <0.05). These data suggest that an important portion
of alanine released into the forearm vein derives from proteol-
ysis. An increased de novo synthesis of alanine can be theorized
owing to a release of alanine in amounts somewhat greater than
phenylalanine. An increased splanchnic uptake of alanine has to
occur [13], since alanine levels were unchanged in patients.
In CRF, peripheral tissues do not extract serine from the
circulation. It is well known that blood levels of serine are
diminished in CRF [12] and that intracellular muscle levels of
the same AA are reduced in hemodialysis patients [46]. The low
levels of senne can curtail its supply to muscle and conse-
quently its uptake by peripheral tissues.
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